integrase strand transfer inhibitor
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
10
The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance
6
Switch rates, time to switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital claim database
11
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
14
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
9
Differential Sensitivities of Retroviruses to Integrase Strand Transfer Inhibitors
6
Altered Viral Fitness and Drug Susceptibility in HIV-1 Carrying Mutations That Confer Resistance to Nonnucleoside Reverse Transcriptase and Integrase Strand Transfer Inhibitors
9
Viral fitness cost prevents HIV 1 from evading dolutegravir drug pressure
7
In vitro activity of dolutegravir against wild type and integrase inhibitor resistant HIV 2
9
In Silicodocking of HIV 1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate
15
AN IN SILICO APPROACH TO IDENTIFY NEW ANTI HIV INTEGRASE INHIBITOR LIKE LEADS BY DOCKING STUDIES
7
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV 1 Integrase Strand Transfer Inhibitors
11
Efficient initiation and strand transfer of polypurine tract-primed plus-strand DNA prevent strand transfer of internally initiated plus-strand DNA.
8
Repair of Gaps in Retroviral DNA Integration Intermediates
10
Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitroand provide a rationale to redesign antiretroviral treatment for feline AIDS
13
HIV Drug Resistance: An Overview
11
Progress in development of HIV 1 integrase inhibitor
15
Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
10
Raltegravir in treatment naïve patients
8
Rous sarcoma virus integrase protein: mapping functions for catalysis and substrate binding.
9